Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	446	emodin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:16
S2	210	S1 and cancer	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 10:41
S3	59	S2 and (phospholipid or phosphatidylcholine)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 10:41
S4	1	S3 and dimyristol	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 10:43
S5	33	S3 and (tyrosine adj1 kinase)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:35
S6	0	S5 and (emodin with (phospholipd or phosphatidylcholine))	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 10:49
S7	0	(emodin with (phospholipd or phosphatidylcholine))	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 10:50
S8	0	trihydroxyanthraquinonoe	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 10:50
S9	99	trihydroxyanthraquinone	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 10:50
S10	11	S9 and emodin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 11:02
S11	2	"6395712".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 11:03
S12	1	S11 and (emodin or liposome or phospholipid or phosphatidylcholine)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 11:05

S13	0	S12 and dimyristol	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 11:05
S14	1	S12 and glycerol	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 11:10
S15	2	"20020156062".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 11:10
S16	2	S15 and (emodin or lipid or phospholipid or lecithin or dimyristol or phosphatidylcholine or cancer or leukemia)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 11:13
S17	1	S15 and (emodin and dimyristoyl)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 11:14
S18	3	(emodin and dimyristoyl)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/04 11:14
S19	2	"5053431".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:16
S20	2	"5316768".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:17
S21	2	"5466455".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:17
S22	2	"6326356".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:17
S23	2	"6328988".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:18
S24	1	S23 and emodin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:19

S25	2	"5514714".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:19
S26	1	S25 and emodin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:19
S27	2	"6444234".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:20
S28	1	S27 and emodin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:20
S29	446	emodin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:35
S30	210	S29 and cancer	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:35
S31	59	S30 and (phospholipid or phosphatidylcholine)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 13:28
S32	33	S31 and (tyrosine adj1 kinase)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:35
S33	32	S32 and (surfactant or Tween or soybean or peanut or detergent)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 11:28
S34	359	claxton.in.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:42
S35	3	S34 and S29	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:43
S36	7110	newman.in.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:44

S37	4	S36 and S29	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:45
S38	0	lopez-berenstein.in.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:46
S39	0	(lopez adj1 berenstein).in.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:46
S40	70	(lopez-berestein).in.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:46
S41	3	S40 and S29	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 07:47
S42	2	"6197754".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 09:16
S43	1	S42 and emodin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 09:55
S44	1	S42 and (surfactant or dmpg or dmpc or phosphatidylcholine or glycerol or soybean or peanut)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 09:45
S45	2	"6395712".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 09:19
S46	1	S45 and (surfactant or dmpg or dmpc or phosphatidylcholine or glycerol or soybean or peanut)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 09:19
S47	1	S42 and (emodin or dmpg or dmpc or phosphatidylcholine or surfactant or soybean or peanut or tween or dimyristol or glycerol)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 10:18
S48	13	dimyristol	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 10:23

S49	1	S48 and (emodin or anthraquinone)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 10:19
S50	1	S48 and S29	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 10:28
S51	66	tween and S29	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 10:28
S52	19	S51 and (soybean or peanut)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 10:44
S53	3146	424/450.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 10:44
S54	13	S53 and S29	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 10:45
S55	177049	(liposome or lipid or lecithin or phosphatidylcholine)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 10:46
S56	13	S54 and S55	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 10:59
S57	0	WO200290313.pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 11:00
S58	0	WO02/90313.ptpn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 11:00
S59	156	boch.in.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 11:29
S60	1	S59 and hydrophobic.ti.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 11:29

S61	0	S60 and tween	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 11:29
S62	1	S60 and surfactant	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 11:30
S63	1	S60 and (soybean or peanut)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 11:32
S64	1747	dimyristoyl	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 11:33
S65	3	S64 and S29	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 13:10
S66	617	514/569.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 13:11
S67	7	S66 and S29	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 13:12
S68	468	424/455.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 13:14
S69	0	S68 and S29	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 13:15
S70	18	anthraquinone with liposome	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 13:23
S71	49	emodin.clm.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 13:49
S72	4830	liposome.clm.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 13:23

S73	1	S72 and S71	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 13:27
S74	0	S70 and emodin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 13:27
S75	2	"4377567".pn.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 13:53
S76	1	S75 and dimyristoyl	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 14:48
S77	0	("4481185".pn. and (cholesterol or fatty or glycol or diglyceried or sterol))	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 15:23
S78	0	tween with preferred	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 15:28
S79	3623	Tween with detergent	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 15:29
S80	0	S79 and (tween with preferred)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 15:30
S81	0	S79 and (tween same preferred)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 15:30

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	19238	((sorbitan with ester) with (detergent or surfactant or emulsifier))	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 15:33
S2	11	S1 with liposome	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 15:34
S3	4	S2 and (tween or monolaurate)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 15:35
S4	5826	S1 and lecithin	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 15:36
S5	1330	S4 and tween	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2005/08/22 15:36

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssptaeval647

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  FEB 28   PATDPAFULL - New display fields provide for legal status
                   data from INPADOC
 NEWS  4  FEB 28   BABS - Current-awareness alerts (SDIs) available
 NEWS  5  MAR 02   GBFULL: New full-text patent database on STN
 NEWS  6  MAR 03   REGISTRY/ZREGISTRY - Sequence annotations enhanced
 NEWS  7  MAR 03   MEDLINE file segment of TOXCENTER reloaded
 NEWS  8  MAR 22   KOREAPAT now updated monthly; patent information enhanced
 NEWS  9  MAR 22   Original IDE display format returns to REGISTRY/ZREGISTRY
 NEWS  10 MAR 22   PATDPASPC - New patent database available
 NEWS  11 MAR 22   REGISTRY/ZREGISTRY enhanced with experimental property tags
 NEWS  12 APR 04   EPFULL enhanced with additional patent information and new
                   fields
 NEWS  13 APR 04   EMBASE - Database reloaded and enhanced
 NEWS  14 APR 18   New CAS Information Use Policies available online
 NEWS  15 APR 25   Patent searching, including current-awareness alerts (SDIs),
                   based on application date in CA/CAplus and USPATFULL/USPAT2
                   may be affected by a change in filing date for U.S.
                   applications.
 NEWS  16 APR 28   Improved searching of U.S. Patent Classifications for
                   U.S. patent records in CA/CAplus
 NEWS  17 MAY 23   GBFULL enhanced with patent drawing images
 NEWS  18 MAY 23   REGISTRY has been enhanced with source information from
                   CHEMCATS
 NEWS  19 JUN 06   The Analysis Edition of STN Express with Discover!
                   (Version 8.0 for Windows) now available
 NEWS  20 JUN 13   RUSSIAPAT: New full-text patent database on STN
 NEWS  21 JUN 13   FRFULL enhanced with patent drawing images
 NEWS  22 JUN 27   MARPAT displays enhanced with expanded G-group definitions
                   and text labels
 NEWS  23 JUL 01   MEDICONF removed from STN
 NEWS  24 JUL 07   STN Patent Forums to be held in July 2005
 NEWS  25 JUL 13   SCISEARCH reloaded
 NEWS  26 JUL 20   Powerful new interactive analysis and visualization software,
                   STN AnaVist, now available
 NEWS  27 AUG 11   Derwent World Patents Index(R) web-based training during
                   August
 NEWS  28 AUG 11   STN AnaVist workshops to be held in North America

 NEWS EXPRESS  JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:55:42 ON 22 AUG 2005

=> file reg
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 12:55:49 ON 22 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   19 AUG 2005  HIGHEST RN 861198-35-8
DICTIONARY FILE UPDATES:  19 AUG 2005  HIGHEST RN 861198-35-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from  *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> s emodin
L1          85 EMODIN

=> file hcaplus uspatfull
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       5.03       5.24

FILE 'HCAPLUS' ENTERED AT 12:56:07 ON 22 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 12:56:07 ON 22 AUG 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> s emodin
L2        2361 EMODIN

=> s dimyristoyl
L3        3796 DIMYRISTOYL

=> s l2 and l3
L4           4 L2 AND L3

=> d l4 1-4 ibib abs

L4   ANSWER 1 OF 4  HCAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:        1991:446028  HCAPLUS Full-text
DOCUMENT NUMBER:         115:46028
TITLE:                   Lipids from fruits of Rumex paulsenianus
AUTHOR(S):               Gusakova, S. D.; Khomova, T. V.; Glushenkova, A. I.
CORPORATE SOURCE:        Inst. Khim. Rastit. Veshchestv, USSR
SOURCE:                  Khimiya Prirodnykh Soedinenii (1990), (5), 604-11
                         CODEN: KPSUAR; ISSN: 0023-1150
DOCUMENT TYPE:           Journal
LANGUAGE:                Russian
AB    Seeds and pericarp comprised 29 and 71 wt.% of R. paulsenianus fruit and
      contained 7.8 and 0.58% lipids, resp.  Thus, the pericarp contribution to
      fruit lipids was ≤15 weight%.  The fruit and seed lipids were almost
      identical.  The fruits contained 11 saturated, and 4 mono-, 2 di-, and one
      (18:3) trienic free fatty acids.  The triacylglycerides contained 2 rare
      monoaceto compds.: 1,3-dimyristoyl-2-acetyl- and 1-myristoyl-2-capronoyl-3-
      acetyl-sn-glyceride, and 1,3-dimyristoyl -2-capronoylglyceride.  C27, C29, and
      C31 comprised ≤78% of fruit paraffins.  Fatty alcs. were 23:0-32:0 alkanols,
      the major ones being 24:0 and 26:0.  The major free sterol was β-sitosterol.
      It was followed by campesterol and stigmasterol.  The identified
      anthraquinones, chrysophanol, physcion and aloe-emodin, were higher in the
      pericarp than in the seeds.

L4   ANSWER 2 OF 4  USPATFULL on STN
ACCESSION NUMBER:        2005:10532  USPATFULL Full-text
TITLE:                   Compositions and methods related to lipid:
                         emodin formulations
INVENTOR(S):             Claxton, David, Hummelstown, PA, UNITED STATES
                         Newman, Robert A., Houston, TX, UNITED STATES
                         Lopez-Berestein, Gabriel, Bellaire, TX, UNITED STATES
PATENT ASSIGNEE(S):      Board of Regents, The University of Texas System (U.S.
                         corporation)
                         The Penn State Research Foundation (U.S. corporation)

                              NUMBER         KIND    DATE
                              -------------- ------ --------
PATENT INFORMATION:           US 2005008664  A1     20050113
APPLICATION INFO.:            US 2003-730361 A1     20031208  (10)

                              NUMBER         DATE
                              -------------- --------
PRIORITY INFORMATION:         US 2002-431422P  20021206 (60)
DOCUMENT TYPE:                Utility
FILE SEGMENT:                 APPLICATION
LEGAL REPRESENTATIVE:         FULBRIGHT & JAWORSKI L.L.P., 600 CONGRESS AVE., SUITE
                              2400, AUSTIN, TX, 78701
NUMBER OF CLAIMS:             37
EXEMPLARY CLAIM:              1
NUMBER OF DRAWINGS:           5 Drawing Page(s)
LINE COUNT:                   1078
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB    The present invention concerns the use of methods and compositions to
      provide an improved lipid:emodin formulation for the treatment of leukemias
      expressing bcr-abl and other cancer with elevated tyrosine kinase activity.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4   ANSWER 3 OF 4  USPATFULL on STN
ACCESSION NUMBER:        2002:280616  USPATFULL Full-text
TITLE:                   Drug delivery system for hydrophobic drugs
INVENTOR(S):             Boch, Ronald Erwin, Vancouver, CANADA
                         Singh, Dev Mitra Ranji, Surrey, CANADA
                         Karmadi, Iman, Vancouver, CANADA

                              NUMBER         KIND    DATE
                              -------------- ------ --------
PATENT INFORMATION:           US 2002156062  A1     20021024
APPLICATION INFO.:            US 2001-833406 A1     20010411  (9)
DOCUMENT TYPE:                Utility
FILE SEGMENT:                 APPLICATION
LEGAL REPRESENTATIVE:         MORRISON & FOERSTER LLP, 3811 VALLEY CENTRE DRIVE,
                              SUITE 500, SAN DIEGO, CA, 92130-2332
NUMBER OF CLAIMS:             20
EXEMPLARY CLAIM:              1
NUMBER OF DRAWINGS:           1 Drawing Page(s)
LINE COUNT:                   1930
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB    Compositions comprising microaggregates containing hydrophobic drugs, as
      well as methods for their production, are described. Such microaggregates
      may include micelle structures or combinations thereof with liposomes, and
      constitute an effective delivery vehicle for a hydrophobic agent. Methods
      for microaggregate production include the use of preferred lipid compounds
      and processing conditions favoring the production of small aggregates for
      improved filter sterilization.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4   ANSWER 4 OF 4  USPATFULL on STN
ACCESSION NUMBER:        2002:119350  USPATFULL Full-text
```

TITLE: Supports for photosensitizer formulations
INVENTOR(S): Chowdhary, Rubinah K., Vancouver, CANADA
Dolphin, David, Vancouver, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20020613330	A1	20020523
APPLICATION INFO.:	US 2001-851606	A1	20010508 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-202640P	20000508 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Kwai Lau, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 3401
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention is generally related to the field of formulating medicaments in association with a solid support. Such formulations comprising photosensitizers, and their use in photodynamic therapy, are also provided. Methods for the production of the medicament formulations are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s lecithin or phospholipid or liposome or phosphatidylcholine
L5 209410 LECITHIN OR PHOSPHOLIPID OR LIPOSOME OR PHOSPHATIDYLCHOLINE

=> s L1 and L5
L6 620 L1 AND L5

=> s L6 and tween
L7 148 L6 AND TWEEN

=> s l7 and (soybean or peanut)
L8 78 L7 AND (SOYBEAN OR PEANUT)

=> s l8 and (dmpc or dmpg or glycerol)
L9 70 L8 AND (DMPC OR DMPG OR GLYCEROL)

=> s l9 and phosphatidylcholine
L10 30 L9 AND PHOSPHATIDYLCHOLINE

=> dup rem
ENTER L# LIST OR (END):l10
PROCESSING COMPLETED FOR L10
L11 30 DUP REM L10 (0 DUPLICATES REMOVED)

=> d 111 20-30 ibib abs

L11 ANSWER 20 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2002:167866 USPATFULL Full-text
TITLE: Acoustically active drug delivery systems
INVENTOR(S): Unger, Evan C., Tucson, AZ, United States

AB The present invention is directed to a pharmaceutical composition including a hydrophobic therapeutic agent having at least one ionizable functional group, and a carrier. The carrier includes an ionizing agent capable of ionizing the functional group, a surfactant, and optionally solubilizers, triglycerides, and neutralizing agents. The invention further relates to a method of preparing such compositions by providing a composition of an ionizable hydrophobic therapeutic agent, an ionizing agent, and a surfactant, and neutralizing a portion of the ionizing agent with a neutralizing agent. The compositions of the invention are particularly suitable for use in oral dosage forms.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 22 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2001:144937 USPATFULL Full-text
TITLE: Solid matrix therapeutic compositions
INVENTOR(S): Unger, Evan C., Tucson, AZ, United States
PATENT ASSIGNEE(S): ImaRx Therapeutics, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001018072	A1	20010830
APPLICATION INFO.:	US 2001-828762	A1	20010409 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-75477, filed on 11 May 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46379P	19970513 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Mackiewicz & Norris LLP, One Liberty Place - 46th Floor, Philadelphia, PA, 19103
NUMBER OF CLAIMS: 38
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 4899
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to a solid porous matrix comprising a surfactant in combination with a bioactive agent. The solid porous matrix may be prepared by combining a surfactant and a therapeutic, together with a solvent, to form an emulsion containing random aggregates of the surfactant and the therapeutic, and processing the emulsion by controlled drying, or controlled agitation and controlled drying to form the solid porous matrix.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 23 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2001:190748 USPATFULL Full-text
TITLE: Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
INVENTOR(S): Patel, Mahesh V., Salt Lake City, UT, United States
Chen, Feng-Jing, Salt Lake City, UT, United States
PATENT ASSIGNEE(S): Lipocine Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT ASSIGNEE(S):	Bristol-Myers Squibb Medical Imaging, Inc., Princeton, NJ, United States (U.S. corporation)		

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6416740	B1	20020709
APPLICATION INFO.:	US 1998-75343		19980511 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46379P	19970513 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Dudash, Diana
ASSISTANT EXAMINER: Sharareh, Shahnam
LEGAL REPRESENTATIVE: Woodcock Washburn LLP
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 5660
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to targeted therapeutic delivery systems comprising a gas or gaseous precursor filled microsphere wherein said gas or gaseous precursor filled microsphere comprises an oil, a surfactant, and a therapeutic compound. Methods of preparing the targeted therapeutic delivery systems are also embodied by the present invention which comprise processing a solution comprising an oil and a surfactant in the presence of a gaseous precursor, at a temperature below the gel to liquid crystalline phase transition temperature of the surfactant to form gas or gaseous precursor filled microsphere, and adding to said microspheres a therapeutic compound resulting in a targeted therapeutic delivery system, wherein said processing is selected from the group consisting of controlled agitation, controlled drying, and a combination thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 21 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2002:102031 USPATFULL Full-text
TITLE: Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
INVENTOR(S): Chen, Feng-Jing, Salt Lake City, UT, United States
Patel, Mahesh V., Salt Lake City, UT, United States
PATENT ASSIGNEE(S): Lipocine, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6383471	B1	20020507
APPLICATION INFO.:	US 1999-287043		19990406 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Bawa, Raj
LEGAL REPRESENTATIVE: Reed, Dianne E., Reed & Associates
NUMBER OF CLAIMS: 114
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3051
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

PATENT INFORMATION:	US 6309663	B1	20011030
APPLICATION INFO.:	US 1999-375636		19990817 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Channavajjala, Lakshmi
LEGAL REPRESENTATIVE: Reed, Dianne E.Reed & Associates
NUMBER OF CLAIMS: 170
EXEMPLARY CLAIM: 1
LINE COUNT: 4371
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to pharmaceutical compositions, pharmaceutical systems, and methods for enhanced absorption of hydrophilic therapeutic agents. Compositions and systems of the present invention include an absorption enhancing carrier, where the carrier is formed from a combination of at least two surfactants, at least one of which is hydrophilic. A hydrophilic therapeutic agent can be incorporated into the composition, or can be co-administered with the composition as part of a pharmaceutical system. The invention also provides methods of treatment with hydrophilic therapeutic agents using these compositions and systems.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 24 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2001:162866 USPATFULL Full-text
TITLE: Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
INVENTOR(S): Patel, Mahesh V., Salt Lake City, UT, United States
Chen, Feng-Jing, Salt Lake City, UT, United States
PATENT ASSIGNEE(S): Lipocine, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6294192	B1	20010925
APPLICATION INFO.:	US 1999-258654		19990226 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Channavajjala, Lakshmi
LEGAL REPRESENTATIVE: Reed, Dianne E.Reed & Associates
NUMBER OF CLAIMS: 74
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 3094
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to triglyceride-free pharmaceutical compositions for delivery of hydrophobic therapeutic agents. Compositions of the present invention include a hydrophobic therapeutic agent and a carrier, where the carrier is formed from a combination of a hydrophilic surfactant and a hydrophobic surfactant. Upon dilution with an aqueous solvent, the composition forms a clear, aqueous dispersion of the surfactants containing the therapeutic agent. The invention also provides methods of treatment with hydrophobic therapeutic agents using these compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 25 OF 30 USPATFULL on STN

ACCESSION NUMBER: 2001:121093 USPATFULL Full-text
TITLE: Clear oil-containing pharmaceutical compositions
INVENTOR(S): Chen, Feng-Jing, Salt Lake City, UT, United States
Patel, Mahesh V., Salt Lake City, UT, United States
PATENT ASSIGNEE(S): Lipocine Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6267985	B1	20010731
APPLICATION INFO.:	US 1999-345615		19990630 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Spear, James M.
LEGAL REPRESENTATIVE: Read, Dianne E.Reed & Associates
NUMBER OF CLAIMS: 184
EXEMPLARY CLAIM: 1
LINE COUNT: 3767
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to pharmaceutical compositions and methods for improved solubilization of triglycerides and improved delivery of therapeutic agents. Compositions of the present invention include a triglyceride and a carrier, where the carrier is formed from a combination of at least two surfactants, at least one of which is hydrophilic. Upon dilution with an aqueous solvent, the composition forms a clear, aqueous dispersion of the triglyceride and surfactants. An optional therapeutic agent can be incorporated into the composition, or can be co-administered with the composition. The invention also provides methods of enhancing triglyceride solubility and methods of treatment with therapeutic agents using these compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 26 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2001:93131 USPATFULL Full-text
TITLE: Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
INVENTOR(S): Patel, Mahesh V., Salt Lake City, UT, United States
Chen, Feng-Jing, Salt Lake City, UT, United States
PATENT ASSIGNEE(S): Lipocine, Inc., Salt Lake City, UT, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6248363	B1	20010619
APPLICATION INFO.:	US 1999-447690		19991123 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Spear, James M.
LEGAL REPRESENTATIVE: Reed, Dianne E.Reed & Associates
NUMBER OF CLAIMS: 57
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 3302
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutrionals, cosmeceuticals and diagnostic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 27 OF 30 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:456858 HCAPLUS Full-text
DOCUMENT NUMBER: 133:94512
TITLE: Improved formulation for topical non-invasive application in vivo
INVENTOR(S): Cevc, Gregor
PATENT ASSIGNEE(S): Idea Innovative Dermale Applikationen G.m.b.H., Germany
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000038653	A1	20000706	WO 1998-EP8421	19981223
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2356080	AA	20000706	CA 1998-2356080	19981223
AU 9925137	A1	20000731	AU 1999-25137	19981223
AU 770803	B2	20040304		
EP 1140021	A1	20011010	EP 1998-966846	19981223
EP 1140021	B1	20040804		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9816113	A	20011023	BR 1998-16113	19981223
JP 2002533379	T2	20021008	JP 2000-590607	19981223
EE 200100342	A	20021015	EE 2001-200100342	19981223
RU 2207844	C2	20030710	RU 2001-120008	19981223
AT 272391	E	20040815	AT 1998-966846	19981223
ES 2226203	T3	20050316	ES 1998-966846	19981223
HR 2001000309	A1	20020630	HR 2001-309	20010502
NO 2001003164	A	20010822	NO 2001-3164	20010622
US 2002064524	A1	20020530	US 2001-887493	20010622
HK 1040629	A1	20050128	HK 2002-102230	20020323

PRIORITY APPLN. INFO.: WO 1998-EP8421 A 19981223
OTHER SOURCE(S): MARPAT 133:94512

AB A formulation comprises mol. arrangements capable of penetrating pores in a barrier, owing to penetrant adaptability, despite the fact that the average diameter of the pores is smaller than the average penetrant diameter, provided that the penetrants can transport agents or cause permeation through the pores after penetrants have entered pores. The formulation comprises at least 1 consistency builder in an amount that increases the formulation to maximally 5 Nm/s so that spreading over is enabled. The formulation also contains 1 antioxidant in an amount that reduces the increase of oxidation index to <100% per 6 mo and/or at least 1 microbicide in an amount that reduces tha bacterial count of 1 million germs added/g of total mass of the formulation to <100 in the case of aerobic bacteria, to <10 in the case of entero-bacteria, and to <1 in the case of Pseudomonas aeruginosa or Staphilococcus aureus, after a period of 4 days. Thus, a composition contained soybean phosphatidylcholine 347, Tween-80 623, sodium dodecyl sulfate 30, benzyl alc. 50, clobetasol 17-propionate 25 and pH 6.5 50 mM phosphate buffer 9000 mg.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 28 OF 30 USPATFULL on STN
ACCESSION NUMBER: 1999:24697 USPATFULL Full-text
TITLE: Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same
INVENTOR(S): Martin, Alain, Ringoas, NJ, United States
PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5874479		19990223
APPLICATION INFO.:	US 1998-19457		19980205
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-224936, filed on 8 Apr 1994, now abandonad And Ser. No. US 1993-53922, filed on 26 Apr 1993, now abandoned which is a continuation of Ser. No. US 1991-663500, filed on 1 Mar 1991, now abandonad		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-38830P	19970206 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Criares, Theodora J.
LEGAL REPRESENTATIVE: Barish, Jean B.
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 3600
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention pertains to therapeutic wound healing compositions for protacting and resuscitating mammalian cells (Embodiment One (I)). This invention also pertains to therapautic permeation enhanced-wound healing compositions for anhancing the penetration of actives into membranas and increasing the proliferation and resuscitation rate of mammalian cells (Embodiment Two (II)). In a first aspect of Embodiment One (I.A), the therapeutic wound healing composition comprises (a) pyruvate, (b) an antioxidant, and (c) a mixture of saturated and unsaturated fatty acids. In a second aspect of Embodiment One (I.B), the tharapeutic wound healing composition comprises (a) pyruvate, (b) lactate, and (c) a mixture of saturated and unsaturated fatty acids. In a third aspect of Embodiment One (I.C), tha therapeutic wound healing composition comprises (a) an antioxidant and (b) a mixture of saturated and unsaturated fatty acids. In a fourth aspect of Embodiment One (I.D), the therapeutic wound healing composition comprises (a) lactate, (b) an antioxidant, and (c) a mixture of saturated and unsaturated fatty acids. In Embodiment Two (II), the therapeutic wound healing compositions of Embodiment One (I.A-D) are combined with a therapeutically effective amount of a permeation enhancing agent (PE) to form permeation enhanced-wound healing compositions (II.A-D+PE). This invention also pertains to methods for preparing and using the permeation enhanced-wound healing compositions and the topical and ingestible pharmaceutical products in which the therapeutic compositions may be used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 29 OF 30 USPATFULL on STN
ACCESSION NUMBER: 97:73663 USPATFULL Full-text
TITLE: Bioadhesive-wound healing compositions and methods for preparing and using same
INVENTOR(S): Martin, Alain, Ringoes, NJ, United States
Leung, Sau-Hung S., Parsippany, NJ, United States
PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5658956		19970819
APPLICATION INFO.:	US 1995-445824		19950522 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-298521, filed on 30 Aug 1994, now abandoned which is a continuation-in-part of Sar. No. US 1993-53922, filed on 26 Apr 1993, now abandoned which is a continuation of Ser. No. US 1991-663500, filed on 1 Mar 1991, now abandoned		

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Criares, Theodora J.
LEGAL REPRESENTATIVE: Barish, Jean B.
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 90 Drawing Figure(s); 77 Drawing Page(s)
LINE COUNT: 5895
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to therapeutic bioadhesive-wound healing compositions useful for treating wounds and increasing the proliferation and resuscitation rate of mammalian cells. The compositions comprise a bioadhesive agent and a therapeutically effective amount of a wound healing composition. In one embodiment the wound healing composition comprises (a) pyruvate; (b) an antioxidant; and (c) a mixture of saturated and unsaturated fatty acids. The therapeutic bioadhesive-wound healing compositions may further comprise medicaments such as entiviral agents, antikeratolytic agents, anti-inflammatory agents, antifungal agents, antibacterial agents, immunostimulating agents, and the like. The bioadhesive-wound healing compositions may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods for preparing and using the bioadhesive-wound healing compositions and the pharmaceutical products in which the compositions may be used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 30 OF 30 USPATFULL on STN
ACCESSION NUMBER: 97:45047 USPATFULL Full-text
TITLE: Cytoprotective wound healing compositions and methods for preparing and using same
INVENTOR(S): Martin, Alain, Ringoes, NJ, United States
PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5633285		19970527
APPLICATION INFO.:	US 1995-446962		19950522 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-312841, filed on 27 Sep 1994, now abandoned which is a continuation of Ser. No. US 1992-841342, filed on 25 Feb 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-663500, filed on 1 Mar 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Criares, Theodore J.		
LEGAL REPRESENTATIVE:	Barish, Jean B.		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	62 Drawing Figure(s); 35 Drawing Page(s)		
LINE COUNT:	4208		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention pertains to therapeutic cytoprotective-wound healing compositions. The compositions comprise a cytotoxic agent and a therapeutic wound healing composition. In one embodiment the wound healing composition comprises (a) pyruvate; (b) an antioxidant; and (c) a mixture of saturated and unsaturated fatty acids. In another embodiment the wound healing composition comprises (a) pyruvate; and, (b) an antioxidant. The therapeutic cytoprotective-wound healing compositions may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods for preparing and using the therapeutic cytoprotective-wound healing compositions and the pharmaceutical products in which the compositions may be used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d l11 10-19 ibib abs

L11 ANSWER 10 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2004:239241 USPATFULL Full-text
TITLE: FcgammaRIIB-specific antibodies and methods of use thereof
INVENTOR(S): Koenig, Scott, Rockville, MD, UNITED STATES
Veri, Maria Concetta, Derwood, MD, UNITED STATES
PATENT ASSIGNEE(S): MacroGenics, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004185045	A1	20040923
APPLICATION INFO.:	US 2003-643857	A1	20030814 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-403266P	20020814 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017	
NUMBER OF CLAIMS:	107	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	29 Drawing Page(s)	
LINE COUNT:	7320	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 11 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2004:196470 USPATFULL Full-text
TITLE: Therapeutic compositions for drug delivery to and through covering epithelia
INVENTOR(S): Pauletti, Giovanni M., Loveland, OH, UNITED STATES
Desai, Kishorkumar J., Westchester, OH, UNITED STATES
Roweton, Susan L., Raleigh, NC, UNITED STATES
Harrison, Donald C., Cincinnati, OH, UNITED STATES
Sanders, Lynda M., Los Altos, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004151774	A1	20040805
APPLICATION INFO.:	US 2003-698794	A1	20031031 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-444634, filed on 22 May 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-425655P	20021112 (60)
	US 2002-423260P	20021031 (60)
	US 2002-424920P	20021108 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HANA VERNY, PETERS, VERNY, JONES & SCHMITT, L.L.P., SUITE 230, 425 SHERMAN AVENUE, PALO ALTO, CA, 94306	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	2483	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polymer foams and films for delivery of therapeutic agents to and through nasal, oral or vaginal mucosa and cornified or non-cornified epithelium of labia and scrotum. Polymer foams or absorbable or non-absorbable films containing a therapeutic agent incorporated therein wherein said agent is released from said foams or films upon placement of said foam or film on the surface epithelium of nasal, oral, or vaginal labia or scrotum. The foam or the film has a controllable rate of gelling, swelling and degradation and is preformed into a device or is applied as a coating to a surface of a more complex drug delivery system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 12 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2004:120135 USPATFULL Full-text
TITLE: Solid matrix therapeutic compositions
INVENTOR(S): Unger, Evan C., Tucson, AZ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004091541	A1	20040513
APPLICATION INFO.:	US 2003-622027	A1	20030716 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-828762, filed on 9 Apr 2001, ABANDONED Division of Ser. No. US 1998-75477, filed on 11 May 1998, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46379P	19970513 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	REED & EBERLE LLP, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025	
NUMBER OF CLAIMS:	38	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	4909	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a solid porous matrix comprising a surfactant in combination with a bioactive agent. The solid porous matrix may be prepared by combining a surfactant and a therapeutic, together with a solvent, to form an emulsion containing random aggregates of the surfactant and the therapeutic, and processing the emulsion by controlled drying, or controlled agitation and controlled drying to form the solid porous matrix.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 13 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2004:94315 USPATFULL Full-text
TITLE: NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
INVENTOR(S): Cevc, Gregor, Gauting, GERMANY, FEDERAL REPUBLIC OF
Vierl, Ulrich, Munchen, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004071767	A1	20040415
APPLICATION INFO.:	US 2003-357617	A1	20030204 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-417847P	20021011 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	EDWARDS & ANGELL, LLP, P.O. BOX 55874, BOSTON, MA, 02205	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	1824	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention describes novel formulations of nonsteroidal anti-inflammatory drugs (NSAIDs) based on complex aggregates with at least three amphipatic components suspended in a suitable, e.g. pharmaceutically acceptable, polar liquid medium. A suitably ionised NSAID is one of the two, amongst said three, components that tends to destabilise lipid membranes, the other system component with such activity being typically a surfactant. In contrast, the remaining amongst said at least three amphipatic components typically forms a stable lipid membrane on it's own. An essential characteristics of the resulting, relatively large, aggregates is an improved ability to penetrate pores, in a semi-permeable barrier, at least 30%, and often much smaller than the average diameter of the complex aggregate. This enables said aggregates to mediate NSAID transport through semi-permeable barriers including mammalian skin. As a result of the skin penetration by NSAID loaded large aggregates, the drug delivered transcutaneously with such carriers gets deeper into the tissue than the corresponding NSAID from a solution on the skin surface. This is believed to be due to the special ability of suitable large carriers to bypass the local sink of blood capillaries at the epidermal-dermal junction in the skin. The carrier-mediated delivery of locally applied NSAIDs thus allows therapy of deep tissues under the drug administration site, which is medically highly desirable.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 14 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2003:306064 USPATFULL Full-text
TITLE: Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
INVENTOR(S): Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003215496	A1	20031120
	US 6923988	B2	20050802
APPLICATION INFO.:	US 2003-428341	A1	20030501 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-800593, filed on 6 Mar 2001, GRANTED, Pat. No. US 6569463 Division of Ser. No. US 1999-447690, filed on 23 Nov 1999, GRANTED, Pat. No. US 6248363		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	REED & EBERLE LLP, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025		
NUMBER OF CLAIMS:	81		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Page(s)		
LINE COUNT:	3364		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier

including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingradients, hydrophilic surfactant, lipophilic surfactants and triglycaridas. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carriar baing formed of differant combinations of pharmaceutical active ingradients, hydrophilic surfactants, lipophilic surfactants and triglycarides. Tha compositions of tha prasant invention can be usad for improved delivery of hydrophilic or hydrophobic pharmacautical active ingredients, such as drugs, nutritional agents, cosmeceuticals and diagnostic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 15 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2003:92739 USPATFULL Full-text
TITLE: SOLID CARRIERS FOR IMPROVED DELIVERY OF HYDROPHOBIC ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS
INVENTOR(S): Patel, Mahesh V., Salt Lake City, UT, UNITED STATES
Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003064097	A1	20030403
	US 6569463	B2	20030527
APPLICATION INFO.:	US 2001-800593	A1	20010306 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-447690, filed on 23 Nov 1999, GRANTED, Pat. No. US 6248363
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: REED & EBERLE LLP, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
NUMBER OF CLAIMS: 91
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 3863
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutrionals, cosmeceuticals and diagnostic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 16 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2002:287094 USPATFULL Full-text
TITLE: Novel acoustically active drug delivery systems
INVENTOR(S): Unger, Evan C., Tucson, AZ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002159952	A1	20021031
APPLICATION INFO.:	US 2002-84855	A1	20020227 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-75343, filed on 11 May 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46379P	19970513 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Woodcock Washburn LLP, One Liberty Place - 46th Floor, Philadelphia, PA, 19103
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 5458
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to targeted therapeutic delivery systems comprising a gas or gaseous precursor filled microsphera wherein said gas or gaseous precursor filled microsphere comprises an oil, a surfactant, and a therapeutic compound. Methods of preparing the targeted therapeutic delivery systems are also embodiad by the present invention which comprise processing a solution comprising an oil and a surfactant in the presence of a gaseous precursor, at a temperatura below the gel to liquid crystalline phase transition temperature of the surfactant to form gas or gaseous precursor filled microsphere, and adding to said microspheres a therapeutic compound resulting in a targeted tharapeutic delivery system, wherein said processing is selected from tha group consisting of controlled agitation, controlled drying, and a combination thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 17 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2002:126014 USPATFULL Full-text
TITLE: Formulation for topical non-invasive application in vivo
INVENTOR(S): Cevc, Gregor, Kirchheim, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002064524	A1	20020530
APPLICATION INFO.:	US 2001-887493	A1	20010622 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1998-EP8421, filed on 23 Dec 1998, UNKNOWN
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DAVIDSON, DAVIDSON & KAPPEL, LLC, 14th Floor, 485 Seventh Avenue, New York, NY, 10018
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 1846
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A formulation comprising molecular arrangements capable of penetrating pores in a barrier, owing to penetrant adaptability, despite the fact that the average diameter of said poras is smaller than the average penetrant diameter, provided that the penetrants can transport agents or else enable agent permeation through the pores after penetrants have entered pores, characterized in that the formulation comprises at least one consistency builder in an amount that increases the formulation to maximally 5 Nm/s so that spreading over, and retention at, the application area is enabled and/or at least one antioxidant in an amount that reduces the increase of oxidation index to less than 100% per 6 months and/or at least one microbicide in an emount that reduces the bacterial count of 1 million germs added per g of total mass of the formulation to less than 100 in the case of aerobic bactaria, to less than 10 in the case of entero-bacteria, and to less then 1 in the case of Pseudomonas aeruginosa or Staphilococcus aureus, after a period of 4 days.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 18 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2002:72457 USPATFULL Full-text
TITLE: SOLID POROUS MATRICES AND METHODS OF MAKING AND USING THE SAME
INVENTOR(S): UNGER, EVAN C., TUCSON, AZ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002039594	A1	20020404
APPLICATION INFO.:	US 1998-75477	A1	19980511 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46379P	19970513 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WOODCOCK WASHBURN KURTZ, MACKIEWICZ AND NORRIS, ONE LIBERTY PLACE 46TH FLOOR, PHILADELPHIA, PA, 19103
NUMBER OF CLAIMS: 106
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 5207
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is diracted to a solid porous matrix comprising a solvent and a surfactant in combination with a bioactive agant. The solvent and the surfactant may, if desired, form vesicles, an agglomeration of which comprisas the matrix. The composition optionally comprises a gas or a gaseous precursor. Tha emulsion may ba dried, and subsequantly reconstituted in an equeous or organic solution.

Tha prasant invention is also directad to a mathod of preparing a solid porous matrix comprising combining a solvent, a surfactant, and a therapeutic to form an emulsion; and processing the emulsion by controlled drying, or controlled agitation and controlled drying to form a solid porous matrix. The resulting solid porous matrix may also comprisa a gas or gasaous pracursor and ba added to a rasuspanding medium.

A method for tha controlled dalivary of a targeted tharapeutic to a region of a patiant is anothar embodiment of tha prasent invention. Tha method comprisas administering to tha patient a composition having a solid porous matrix comprising a solvant, a surfactant, a tharapeutic, and a gas or gaseous precursor, monitoring the composition using anargy to datarmina tha presence of the composition in the region; and releasing the therapeutic from the composition in the region using energy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 19 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2002:21845 USPATFULL Full-text
TITLE: Compositions and methods for improved delivery of lipid regulating agents
INVENTOR(S): Patal, Mahesh V., Salt Lake City, UT, UNITED STATES
Chen, Feng-Jing, Salt Lake City, UT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002012680	A1	20020131
	US 6451339	B2	20020917
APPLICATION INFO.:	US 2001-898553	A1	20010702 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-258654, filed on 26 Feb 1999, GRANTED, Pat. No. US 6294192
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
NUMBER OF CLAIMS: 140
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 3604
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invantion relatas to triglyceride-fraa pharmacautical compositions for delivery of hydrophobic therapeutic agents. Compositions of the present invention include a hydrophobic therapautic agent and a carriar, where the carrier is formed from a combination of a hydrophilic surfactant and a hydrophobic surfactant. Upon dilution with an aquaous solvent, the composition forms a clear, equeous dispersion of tha surfactants containing tha therapeutic agent. Tha invention also provides methods of treatment with hydrophobic tharapeutic egants using thesa compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his full

(FILE 'HOME' ENTERED AT 12:55:42 ON 22 AUG 2005)

FILE 'REGISTRY' ENTERED AT 12:55:49 ON 22 AUG 2005
L1 85 SEA EMODIN

FILE 'HCAPLUS, USPATFULL' ENTERED AT 12:56:07 ON 22 AUG 2005
L2 2361 SEA EMODIN
L3 3796 SEA DIMYRISTOYL
L4 4 SEA L2 AND L3
D L4 1-4 IBIB ABS
L5 209410 SEA LECITHIN OR PHOSPHOLIPID OR LIPOSOME OR PHOSPHATIDYLCHOLINE

L6 620 SEA L1 AND L5
L7 148 SEA L6 AND TWEEN
L8 78 SEA L7 AND (SOYBEAN OR PEANUT)
L9 70 SEA L8 AND (DMPC OR DMPG OR GLYCEROL)

```
L10         30 SEA L9 AND PHOSPHATIDYLCHOLINE
L11         30 DUP REM L10 (0 DUPLICATES REMOVED)
               D L11 20-30 IBIB ABS
               D L11 10-19 IBIB ABS


FILE HOME

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   19 AUG 2005  HIGHEST RN 861198-35-8
DICTIONARY FILE UPDATES:  19 AUG 2005  HIGHEST RN 861198-35-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************
*                                                        *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                        *
**********************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

FILE HCAPLUS

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 22 Aug 2005  VOL 143 ISS 9
FILE LAST UPDATED: 21 Aug 2005  (20050821/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 18 Aug 2005 (20050818/PD)
FILE LAST UPDATED: 18 Aug 2005 (20050818/ED)
HIGHEST GRANTED PATENT NUMBER: US6931661
HIGHEST APPLICATION PUBLICATION NUMBER: US2005183181
CA INDEXING IS CURRENT THROUGH 18 Aug 2005 (20050818/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 18 Aug 2005 (20050818/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2005

>>> USPAT2 is now available.  USPATFULL contains full text of the      <<<
>>> original, i.e., the earliest published granted patents or         <<<
>>> applications.  USPAT2 contains full text of the latest US         <<<
>>> publications, starting in 2001, for the inventions covered in     <<<
>>> USPATFULL.  A USPATFULL record contains not only the original     <<<
>>> published document but also a list of any subsequent              <<<
>>> publications.  The publication number, patent kind code, and      <<<
>>> publication date for all the US publications for an invention      <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL   <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc.                                                         <<<

>>> USPATFULL and USPAT2 can be accessed and searched together         <<<
>>> through the new cluster USPATALL.  Type FILE USPATALL to           <<<
>>> enter this cluster.                                               <<<
>>>                                                                  <<<
>>> Use USPATALL when searching terms such as patent assignees,       <<<
>>> classifications, or claims, that may potentially change from      <<<
>>> the earliest to the latest publication.                           <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d l11 1-9 ibib abs

L11  ANSWER 1 OF 30  USPATFULL on STN
ACCESSION NUMBER:         2005:177866  USPATFULL Full-text
TITLE:                    Methods and reagents for the treatment of diseases and
                          disorders associated with increased levels of
                          proinflammatory cytokines
INVENTOR(S):              Padval, Mahesh, Waltham, MA, UNITED STATES
                          Jost-Price, Edward Roydon, West Roxbury, MA, UNITED
                          STATES
                          Manivasakam, Palaniyandi, West Roxbury, MA, UNITED
                          STATES
                          Smith, Brendan, Boston, MA, UNITED STATES
                          Fong, Jason, Philadelphia, PA, UNITED STATES
                          Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
                          Nichols, M. James, Boston, MA, UNITED STATES
                          Keith, Curtis, Boston, MA, UNITED STATES
                          Zimmerman, Grant R., Somervillle, MA, UNITED STATES
                          Brasher, Bradley B., Natick, MA, UNITED STATES
                          Sachs, Noah, Boston, MA, UNITED STATES
                          Chappell, Todd W., Boston, MA, UNITED STATES

                              NUMBER         KIND    DATE
                              -------------- ------ --------
PATENT INFORMATION:       US 2005153947      A1   20050714
APPLICATION INFO.:        US 2004-947455     A1   20040920  (10)
RELATED APPLN. INFO.:     Continuation of Ser. No. US 2004-777517, filed on 12
                          Feb 2004, PENDING Continuation-in-part of Ser. No. US
                          2003-670488, filed on 24 Sep 2003, PENDING

                              NUMBER         DATE
                              -------------- --------
PRIORITY INFORMATION:     US 2002-413040P    20020924 (60)
                          US 2002-417261P    20021009 (60)
                          US 2002-427424P    20021119 (60)
                          US 2002-427526P    20021119 (60)
                          US 2003-464753P    20030423 (60)
DOCUMENT TYPE:            Utility
FILE SEGMENT:             APPLICATION
LEGAL REPRESENTATIVE:     CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA,
                          02110, US
NUMBER OF CLAIMS:         3
EXEMPLARY CLAIM:          1
LINE COUNT:               2921
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB    The invention features a method for treating a patient diagnosed with, or at
      risk of developing, an immunoinflammatory disorder by administering an SSRI
      or analog or metabolite thereof and, optionally, a corticosteroid or other
      compound to the patient. The invention also features a pharmaceutical
      composition containing an SSRI or analog or metabolite thereof and a
      corticosteroid or other compound for the treatment or prevention of an
      immunoinflammatory disorder.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 2 OF 30  USPATFULL on STN
ACCESSION NUMBER:         2005:165911  USPATFULL Full-text
TITLE:                    Methods and compositions for improved non-viral gene
                          therapy
INVENTOR(S):              Ramesh, Rajagopal, Sugar Land, TX, UNITED STATES
                          Gopalan, Began, Houston, TX, UNITED STATES
                          Roth, Jack A., Houston, TX, UNITED STATES
PATENT ASSIGNEE(S):       Board of Regents, The University of Texas System (U.S.
                          corporation)

                              NUMBER         KIND    DATE
                              -------------- ------ --------
PATENT INFORMATION:       US 2005143336      A1   20050630
APPLICATION INFO.:        US 2004-341        A1   20041130  (11)

                              NUMBER         DATE
                              -------------- --------
PRIORITY INFORMATION:     US 2003-533180P    20031230 (60)
DOCUMENT TYPE:            Utility
FILE SEGMENT:             APPLICATION
LEGAL REPRESENTATIVE:     FULBRIGHT & JAWORSKI L.L.P., 600 CONGRESS AVE., SUITE
                          2400, AUSTIN, TX, 78701, US
NUMBER OF CLAIMS:         41
EXEMPLARY CLAIM:          1
NUMBER OF DRAWINGS:       17 Drawing Page(s)
LINE COUNT:               4301
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB    Methods to prevent or reduce inflammation secondary to administration of a
      lipid-nucleic acid complex in a subject, that include administering to the
      subject a non-steroidal anti-inflammatory agent, a salicylate, an anti-
      rheumatic agent, an antihistamine, or an immunosuppressive agent with the
      lipid-nucleic acid complex are disclosed. Also disclosed are methods of
      screening for inhibitors of the inflammatory response associated with
      administration of a lipid-nucleic acid complex to a subject, including
      providing a candidate substance suspected of preventing or inhibiting the
      inflammation associated with administration of a lipid-nucleic acid complex
      to the subject. Also disclosed are compositions that include a lipid, a
      nucleic acid, and a non-steroidal anti-inflammatory agent, a salicylate, an
      anti-rheumatic agent, an antihistamine, or an immunosuppressive agent.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 3 OF 30  USPATFULL on STN
ACCESSION NUMBER:         2005:143867  USPATFULL Full-text
TITLE:                    Rifalazil formulations
INVENTOR(S):              Michaelis, Arthur F., Devon, PA, UNITED STATES

                              NUMBER         KIND    DATE
                              -------------- ------ --------
PATENT INFORMATION:       US 2005123602      A1   20050609
APPLICATION INFO.:        US 2004-950917     A1   20040927  (10)

                              NUMBER         DATE
                              -------------- --------
PRIORITY INFORMATION:     US 2003-506107P    20030925 (60)
DOCUMENT TYPE:            Utility
FILE SEGMENT:             APPLICATION
LEGAL REPRESENTATIVE:     CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA,
                          02110, US
NUMBER OF CLAIMS:         28
EXEMPLARY CLAIM:          1
NUMBER OF DRAWINGS:       3 Drawing Page(s)
LINE COUNT:               1636
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB    The invention features pharmaceutical compositions including rifalazil and a
      micelle-forming excipient and methods of use thereof.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11  ANSWER 4 OF 30  USPATFULL on STN
ACCESSION NUMBER:         2005:138510  USPATFULL Full-text
TITLE:                    Methods and reagents for the treatment of
                          immunoinflammatory disorders
INVENTOR(S):              Keith, Curtis, Boston, MA, UNITED STATES
                          Borisy, Alexis, Arlington, MA, UNITED STATES
                          Zimmermann, Grant R., Somerville, MA, UNITED STATES
                          Jost-Price, Edward Roydon, West Roxbury, MA, UNITED
                          STATES
                          Manivasakam, Palaniyandi, Brighton, MA, UNITED STATES
                          Hurst, Nicole, Boston, MA, UNITED STATES
                          Foley, Michael A., Chestnut Hill, MA, UNITED STATES
                          Slavonic, Michael S., Quincy, MA, UNITED STATES
                          Smith, Brendan, Boston, MA, UNITED STATES
                          Auspitz, Benjamin A., Cambridge, MA, UNITED STATES

                              NUMBER         KIND    DATE
                              -------------- ------ --------
PATENT INFORMATION:       US 2005119160      A1   20050602
APPLICATION INFO.:        US 2004-966228     A1   20041015  (10)
```

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-512415P	20031015 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
NUMBER OF CLAIMS: 53
EXEMPLARY CLAIM: 1
LINE COUNT: 4196
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient a tetra-substituted pyrimidopyrimidine, either alone or in combination with one or more additional agents. The invention also features a composition containing a tetra-substituted pyrimidopyrimidine in combination with one or more additional agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 5 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2005:10532 USPATFULL Full-text
TITLE: Compositions and methods related to lipid:emodin formulations
INVENTOR(S): Claxton, David, Hummelstown, PA, UNITED STATES
Newman, Robert A., Houston, TX, UNITED STATES
Lopez-Berestein, Gabriel, Bellaire, TX, UNITED STATES
PATENT ASSIGNEE(S): Board of Regents, The University of Texas System (U.S. corporation)
The Penn State Research Foundation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005008664	A1	20050113
APPLICATION INFO.:	US 2003-730361	A1	20031208 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-431422P	20021206 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FULBRIGHT & JAWORSKI L.L.P., 600 CONGRESS AVE., SUITE 2400, AUSTIN, TX, 78701
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 1078
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns the use of methods and compositions to provide an improved lipid:emodin formulation for the treatment of leukemias expressing bcr-abl and other cancer with elevated tyrosine kinase activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 6 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2004:320591 USPATFULL Full-text
TITLE: Methods for treating pain by administering a nerve growth factor antagonist and an NSAID and compositions containing the same
INVENTOR(S): Shelton, David L., Oakland, CA, UNITED STATES
Vergara, German J., Moraga, CA, UNITED STATES
Loo, Carole M., San Mateo, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004253244	A1	20041216
APPLICATION INFO.:	US 2004-783730	A1	20040219 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-448823P	20030219 (60)
	US 2003-448853P	20030219 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO, CA, 94304-1018
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 2529
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention features methods for treating or preventing pain comprising administering an amount of a nerve growth factor antagonist (such as an anti-NGF antibody) and an amount of an NSAID such that together they provide effective pain relief. The invention also features compositions comprising a nerve growth factor antagonist and an NSAID and kits containing the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 7 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2004:292760 USPATFULL Full-text
TITLE: Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
INVENTOR(S): Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Manivasakam, Palaniyandi, West Roxbury, MA, UNITED STATES
Smith, Brendan, Boston, MA, UNITED STATES
Fong, Jason, Philadelphia, PA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
Nichols, M. James, Boston, MA, UNITED STATES
Keith, Curtis, Boston, MA, UNITED STATES
Zimmermann, Grant R., Somerville, MA, UNITED STATES
Brasher, Bradley B., Natick, MA, UNITED STATES
Sachs, Noah, Boston, MA, UNITED STATES
Chappell, Todd W., Boston, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004229849	A1	20041118
APPLICATION INFO.:	US 2004-777517	A1	20040212 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-670488, filed on 24 Sep 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-413040P	20020924 (60)
	US 2002-417261P	20021009 (60)
	US 2002-427526P	20021119 (60)
	US 2002-427424P	20021119 (60)
	US 2003-464753P	20030423 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110
NUMBER OF CLAIMS: 86
EXEMPLARY CLAIM: 1
LINE COUNT: 3245
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering an SSRI or analog or metabolite thereof and, optionally, a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing an SSRI or analog or metabolite thereof and a corticosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 8 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2004:286708 USPATFULL Full-text
TITLE: Combination therapy for the treatment of immunoinflammatory disorders
INVENTOR(S): Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Brasher, Bradley B., Natick, MA, UNITED STATES
Chappell, Todd W., Boston, MA, UNITED STATES
Manivasakam, Palaniyandi, West Roxbury, MA, UNITED STATES
Sachs, Noah, Boston, MA, UNITED STATES
Smith, Brendan, Boston, MA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004224876	A1	20041111
APPLICATION INFO.:	US 2004-777518	A1	20040212 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-447366P	20030214 (60)
	US 2003-447412P	20030214 (60)
	US 2003-447415P	20030214 (60)
	US 2003-447553P	20030214 (60)
	US 2003-447648P	20030214 (60)
	US 2003-464753P	20030423 (60)
	US 2003-503026P	20030915 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110
NUMBER OF CLAIMS: 61
EXEMPLARY CLAIM: 1
LINE COUNT: 3770
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering a non-steroidal immunophilin-dependent immunosuppressant (NsIDI) and an NsIDI enhancer (NsIDIE) or analog or metabolite thereof to the patient. The invention also features a pharmaceutical composition containing an NsIDI and NsIDIE or analog or metabolite thereof for the treatment or prevention of an immunoinflammatory disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 9 OF 30 USPATFULL on STN
ACCESSION NUMBER: 2004:280852 USPATFULL Full-text
TITLE: Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
INVENTOR(S): Jost-Price, Edward Roydon, West Roxbury, MA, UNITED STATES
Manivasakam, Palaniyandi, W. Roxbury, MA, UNITED STATES
Smith, Brendan, Boston, MA, UNITED STATES
Fong, Jason, Philadelphia, PA, UNITED STATES
Auspitz, Benjamin A., Cambridge, MA, UNITED STATES
Nichols, M. James, Boston, MA, UNITED STATES
Keith, Curtis, Boston, MA, UNITED STATES
Zimmermann, Grant R., Somerville, MA, UNITED STATES
Brasher, Bradley B., Natick, MA, UNITED STATES
Sachs, Noah, Boston, MA, UNITED STATES
Chappell, Todd W., Boston, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004220153	A1	20041104
APPLICATION INFO.:	US 2003-670488	A1	20030924 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-413040P	20020924 (60)
	US 2002-417261P	20021009 (60)
	US 2002-427526P	20021119 (60)
	US 2003-464753P	20030423 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110
NUMBER OF CLAIMS: 77
EXEMPLARY CLAIM: 1
LINE COUNT: 3183
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering an SSRI or analog or metabolite thereof and, optionally, a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing an SSRI or analog or metabolite thereof and a corticosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
=> d his full

     (FILE 'HOME' ENTERED AT 12:55:42 ON 22 AUG 2005)

     FILE 'REGISTRY' ENTERED AT 12:55:49 ON 22 AUG 2005
L1            85 SEA EMODIN

     FILE 'HCAPLUS, USPATFULL' ENTERED AT 12:56:07 ON 22 AUG 2005
L2          2361 SEA EMODIN
L3          3796 SEA DIMYRISTOYL
L4             4 SEA L2 AND L3
               D L4 1-4 IBIB ABS
L5        209410 SEA LECITHIN OR PHOSPHOLIPID OR LIPOSOME OR PHOSPHATIDYLCHOLINE

L6            620 SEA L1 AND L5
L7            148 SEA L6 AND TWEEN
L8             78 SEA L7 AND (SOYBEAN OR PEANUT)
L9             70 SEA L8 AND (DMPC OR DMPG OR GLYCEROL)
L10            30 SEA L9 AND PHOSPHATIDYLCHOLINE
L11            30 DUP REM L10 (0 DUPLICATES REMOVED)
               D L11 20-30 IBIB ABS
               D L11 10-19 IBIB ABS
               D L11 1-9 IBIB ABS


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   19 AUG 2005  HIGHEST RN 861198-35-8
     DICTIONARY FILE UPDATES:  19 AUG 2005  HIGHEST RN 861198-35-8

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     ************************************************************
     *                                                          *
     * The CA roles and document type information have been removed from *
     * the IDE default display format and the ED field has been added,   *
     * effective March 20, 2005.  A new display format, IDERL, is now    *
     * available and contains the CA role and document type information. *
     *                                                          *
     ************************************************************

     Structure search iteration limits have been increased.  See HELP SLIMITS
     for details.

     Experimental and calculated property data are now available. For more
     information enter HELP PROP at an arrow prompt in the file or refer
     to the file summary sheet on the web at:
     http://www.cas.org/ONLINE/DBSS/registryss.html

     FILE HCAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     the American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storing
     of this information, without the prior written consent of CAS, is
     strictly prohibited.

     FILE COVERS 1907 - 22 Aug 2005  VOL 143 ISS 9
     FILE LAST UPDATED: 21 Aug 2005  (20050821/ED)

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

      This file contains CAS Registry Numbers for easy and accurate
      substance identification.

     FILE USPATFULL
     FILE COVERS 1971 TO PATENT PUBLICATION DATE: 18 Aug 2005 (20050818/PD)
     FILE LAST UPDATED: 18 Aug 2005 (20050818/ED)
     HIGHEST GRANTED PATENT NUMBER: US6931661
     HIGHEST APPLICATION PUBLICATION NUMBER: US2005183181
     CA INDEXING IS CURRENT THROUGH 18 Aug 2005 (20050818/UPCA)
     ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 18 Aug 2005 (20050818/PD)
     REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2005
     USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2005

     >>>  USPAT2 is now available.  USPATFULL contains full text of the      <<<
     >>>  original, i.e., the earliest published granted patents or          <<<
     >>>  applications.  USPAT2 contains full text of the latest US          <<<
     >>>  publications, starting in 2001, for the inventions covered in      <<<
     >>>  USPATFULL.  A USPATFULL record contains not only the original      <<<
     >>>  published document but also a list of any subsequent               <<<
     >>>  publications.  The publication number, patent kind code, and       <<<
     >>>  publication date for all the US publications for an invention      <<<
     >>>  are displayed in the PI (Patent Information) field of USPATFULL    <<<
     >>>  records and may be searched in standard search fields, e.g., /PN,  <<<
     >>>  /PK, etc.                                                          <<<

     >>>  USPATFULL and USPAT2 can be accessed and searched together         <<<
     >>>  through the new cluster USPATALL.  Type FILE USPATALL to           <<<
     >>>  enter this cluster.                                               <<<
     >>>                                                                    <<<
     >>>  Use USPATALL when searching terms such as patent assignees,       <<<
     >>>  classifications, or claims, that may potentially change from      <<<
     >>>  the earliest to the latest publication.                           <<<

     This file contains CAS Registry Numbers for easy and accurate
     substance identification.

=> log h
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                              ENTRY     SESSION
FULL ESTIMATED COST                             98.19      103.43

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  SINCE FILE      TOTAL
                                              ENTRY     SESSION
CA SUBSCRIBER PRICE                             -1.46       -1.46


 SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:06:02 ON 22 AUG 2005
```